Christine Karell, APRN
Psychiatric/Mental Health · Alliance, NENPI 1053480590
Payments from drug & device makers
Across 150 payments — averaging $19.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$589
- Teva Pharmaceuticals USA, Inc.$561
- AbbVie$483
- Otsuka America Pharmaceutical, Inc.$349
- Alkermes, Inc.$321
- Johnson & Johnson$252
- plus $333 from 10 others
What the payments were for
- Food & beverage$2,70494%
- Education$1836%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $589 |
| Teva Pharmaceuticals USA, Inc. | 30 | $561 |
| AbbVie | 23 | $483 |
| Otsuka America Pharmaceutical, Inc. | 19 | $349 |
| Alkermes, Inc. | 20 | $321 |
| Johnson & Johnson | 13 | $252 |
| Supernus Pharmaceuticals, Inc. | 7 | $111 |
| Neurocrine Biosciences, Inc. | 3 | $48 |
| Lilly USA, LLC | 2 | $46 |
| Axsome Therapeutics, Inc. | 2 | $32 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Novartis | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Corium, LLC | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Adlon Therapeutics L.p. | 1 | $13 |
How this compares
$2,887 in reported general payments places this provider in the 70th percentile of 255 psychiatric/mental health providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 61 | $216,770 |
| IngrezzaValbenazine Tosylate | 18 | $139,372 |
| AristadaAripiprazole Lauroxil | 13 | $47,042 |
| VraylarCariprazine Hcl | 20 | $45,274 |
| Wellbutrin XlBupropion Hcl | 17 | $38,027 |
| TrintellixVortioxetine Hydrobromide | 66 | $37,879 |
| RexultiBrexpiprazole | 25 | $34,655 |
| Lurasidone Hcl | 58 | $27,411 |
| Aripiprazole | 183 | $24,313 |
| CaplytaLumateperone Tosylate | 11 | $16,820 |
| SpravatoEsketamine Hcl | 11 | $15,966 |
| Paliperidone ErPaliperidone | 70 | $15,261 |
| MounjaroTirzepatide | 14 | $12,758 |
| FetzimaLevomilnacipran Hcl | 18 | $9,053 |
| VyvanseLisdexamfetamine Dimesylate | 21 | $8,506 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Spravato | $252 | $232,73672 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $48 | $139,37218 claims |
| AbbVieVraylar, Fetzima | $483 | $54,32838 claims |
| Alkermes, Inc.Aristada | $321 | $47,04213 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $349 | $34,65525 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $589 | $16,82011 claims |
| Lilly USA, LLCMounjaro | $46 | $12,75814 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $111 | $6,55917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 255 psychiatric/mental health providers in Nebraska.
Other psychiatric/mental health in Alliance
- Dacia OakesonHastings$32K
- Margaret Emersonla Vista$30K
- Janelle HillOmaha$24K
- Kristi BoseOmaha$13K
- Robert LundholmOmaha$12K
- Sherry KropatschGrand Island$11K
- Virginia SmithOmaha$11K
- Christina HadleyOmaha$11K
- Suzanne GreggHastings$11K
- Helen TrotterLincoln$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.